Bridging The Gap Between mAbs And Next-Generation Therapeutics

The inherent complexity of certain molecules, like bispecific antibodies and Fc-fusion proteins, can impose additional challenges during development when compared to monoclonal antibodies (mAbs). FUJIFILM Diosynth Biotechnologies' Apollo™ X expression system and associated technologies provide versatile solutions that are compatible with a diverse range of biotherapeutics including bispecific and Fc-fusion molecules. In this presentation, we demonstrate the system's ability to express these proteins efficiently through a streamlined development process.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

FUJIFILM Diosynth Biotechnologies